These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 9793590)
61. Cerebrospinal fluid formation in ventricles and spinal subarachnoid space of the rhesus monkey. Lux WE; Fenstermacher JD J Neurosurg; 1975 Jun; 42(6):674-8. PubMed ID: 1095693 [TBL] [Abstract][Full Text] [Related]
62. Monitoring central nervous system methotrexate levels via subcutaneous reservoir. Sources of errors in sampling and their avoidance. Maguire LC; Corder MP; Wiesenfeld M Cancer Clin Trials; 1980; 3(4):337-40. PubMed ID: 6893574 [TBL] [Abstract][Full Text] [Related]
63. Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine. Damon LE; Plunkett W; Linker CA Cancer Res; 1991 Aug; 51(16):4141-5. PubMed ID: 1868435 [TBL] [Abstract][Full Text] [Related]
64. Magnesium concentrations in the ventricular and lumbar cerebrospinal fluid of hypomagnesaemic cows. Allsop TF; Pauli JV Res Vet Sci; 1985 Jan; 38(1):61-4. PubMed ID: 3975484 [TBL] [Abstract][Full Text] [Related]
65. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia. Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460 [TBL] [Abstract][Full Text] [Related]
66. Elevated concentration of hyaluronan in the cerebrospinal fluid is a secondary marker of spinal disorders: hyaluronan in the cerebrospinal fluid in patients with spinal disorders. Sakayama K; Kidani T; Sugawara Y; Masuno H; Matsuda Y; Yamamoto H J Spinal Disord Tech; 2006 Jun; 19(4):262-5. PubMed ID: 16778660 [TBL] [Abstract][Full Text] [Related]
67. [Successful recovery of an acute myelogenous leukemia patient from a coma possibly due to leukoencephalopathy]. Doki N; Saito Y; Hatsumi N; Irisawa H; Sakura T; Miyawaki S Rinsho Ketsueki; 2003 Nov; 44(11):1090-4. PubMed ID: 14689873 [TBL] [Abstract][Full Text] [Related]
68. Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia. Michel G; Landman-Parker J; Auclerc MF; Mathey C; Leblanc T; Legall E; Bordigoni P; Lamagnere JP; Demeocq F; Perel Y; Auvrignon A; Berthou C; Bauduer F; Pautard B; Schneider P; Schaison G; Leverger G; Baruchel A J Clin Oncol; 2000 Apr; 18(7):1517-24. PubMed ID: 10735900 [TBL] [Abstract][Full Text] [Related]
69. Intraventricular and lumbar intrathecal administration of antibiotics in postneurosurgical patients with meningitis and/or ventriculitis in a serious clinical state. Remeš F; Tomáš R; Jindrák V; Vaniš V; Setlík M J Neurosurg; 2013 Dec; 119(6):1596-602. PubMed ID: 23952688 [TBL] [Abstract][Full Text] [Related]
72. Development and Validation of an HPLC Method for Analysis of Topotecan in Human Cerebrospinal Fluid and Its Application in Elimination Evaluation of Topotecan after Intraventricular Injection. Yoshikawa N; Yamada A; Yokota T; Yamada Y; Kinoshita M; Moritake H; Ikeda R Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572867 [TBL] [Abstract][Full Text] [Related]
73. Analysis of methotrexate in cerebrospinal fluid by fluorescence polarization immunoassay. Glasco GB; Taylor EH; Chadduck WM; Pappas AA Drug Intell Clin Pharm; 1988 Nov; 22(11):912-3. PubMed ID: 3069430 [No Abstract] [Full Text] [Related]
74. Integrated pharmacokinetics and pharmacodynamics in drug development. Dingemanse J; Appel-Dingemanse S Clin Pharmacokinet; 2007; 46(9):713-37. PubMed ID: 17713971 [TBL] [Abstract][Full Text] [Related]
75. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. de Lange EC; Danhof M Clin Pharmacokinet; 2002; 41(10):691-703. PubMed ID: 12162757 [TBL] [Abstract][Full Text] [Related]
76. Pharmacokinetics of anticancer drugs in cerebrospinal fluid. Morikawa N; Mori T; Kawashima H; Takeyama M; Hori S Ann Pharmacother; 1998 Oct; 32(10):1008-12. PubMed ID: 9793590 [TBL] [Abstract][Full Text] [Related]
77. Pharmacokinetics of cytosine arabinoside, methotrexate, nimustine and valproic acid in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy. Morikawa N; Mori T; Abe T; Kawashima H; Takeyama M; Hori S Biol Pharm Bull; 2000 Jun; 23(6):784-7. PubMed ID: 10864038 [TBL] [Abstract][Full Text] [Related]
78. Pharmacokinetics of nimustine, cytosine arabinoside, and methotrexate in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy. Morikawa N; Mori T; Kawashima H; Takeyama M; Abe T; Kobayashi H Biol Pharm Bull; 2001 Apr; 24(4):436-8. PubMed ID: 11305611 [TBL] [Abstract][Full Text] [Related]
79. Pharmacokinetics of nimustine, methotrexate, and cytosine arabinoside during cerebrospinal fluid perfusion chemotherapy in patients with disseminated brain tumors. Morikawa N; Mori T; Kawashima H; Fujiki M; Abe T; Kaku T; Konisi Y; Takeyama M; Hori S Eur J Clin Pharmacol; 1998 Jul; 54(5):415-20. PubMed ID: 9754986 [TBL] [Abstract][Full Text] [Related]
80. Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Fleischhack G; Jaehde U; Bode U Clin Pharmacokinet; 2005; 44(1):1-31. PubMed ID: 15634030 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]